Vantia Therapeutics Ltd.

Vantia launched in 2007 around small-molecule assets spun out of Ferring Pharmaceuticals, and it's rapidly advancing its pipeline in urology, pain, inflammation and other diseases. It has a Phase II vasopressin 2 agonist for nocturia, a Phase II vasopressin antagonist for dysmenorrhea, and several earlier-stage research programs.